Orchid Pharma growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+33.7%+12.5%+23.0%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
−71.3%+5.9%+32.4%
−111.7%+6.7%+168.6%
−90.0%+8.1%+99.0%
−91.6%+3.1%+67.9%
+33.8%+8.6%+26.8%
+23.4%+8.4%+69.8%
+553.8%−84.7%+578.0%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

ORCHPHARMA₹893.40

Orchid Pharma Limited

· Pharma & Health
₹ CrorePeersFDCGUJTHEMIOLCPMOREPENLABRPGLIFEGUFICBIOINNOVACAPUNICHEMLABMcap ₹5,350 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—+23.0+12.5+33.7—
EBITDA Growth—+32.4+5.9-71.3—
EBIT Growth—+168.6+6.7-111.7—
Net Income Growth—+99.0+8.1-90.0—
EPS Growth—+67.9+3.1-91.6—
Total Assets Growth—+26.8+8.6+33.8—
Total Equity Growth—+69.8+8.4+23.4—
Cash from Operations Growth—+578.0-84.7+553.8—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.